Characteristics of B-CLL Patients
| Patient No. . | Age/ Sex . | Stage* . | WBC . | CD5 . | CD19 . | CD22 . | CD23 . | FMC7 . | κ/λ . | CD79b . | β2M . | +12 . | Previous Treatment . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 72/M | A | 180 | 99 | 90 | 93+ | 50 | 2 | 0/93++ | 84++ | 6.4 | Yes | CLB |
| 2 | 61/M | A | 68 | 95 | 84 | 77+ | 85 | 4 | 79+/0 | 27dim | 2 | ND | No |
| 3 | 67/F | C | 163 | 68 | 90 | 15 dim | 87 | 0 | 0/88 | 19 | ND | No | No |
| 4 | 77/F | A | 107 | 85 | 59 | 38+ | 43 | 14 | 17/0 | ND | 2 | ND | No |
| 5 | 63/F | A | 87 | 97 | 90 | 84+/++ | 64 | 5 | 63/0 | ND | ND | ND | No |
| 6 | 69/F | A | 19 | 94 | 69 | 74 | 25 | 6 | 45+/0 | 53+ | ND | No | No |
| 7 | 47/M | B | 425 | 96 | 95 | 70+ | 95 | 7 | 0/93+/++ | ND | 5.4 | ND | 2-CDA |
| 8 | 70/M | A | 31 | 91 | 87 | 88+ | 78 | 14 | 86+/0 | ND | 6.2 | No | CLB/PDN; FLU |
| 9 | 47/M | B | 18 | 97 | 92 | 54+ | 90 | 16 | 54+/0 | ND | 2.5 | ND | CLB; FLU |
| 10 | 84/F | A | 154 | 96 | 93 | 93+ | 41 | 0 | 91+/0 | 90+ | 4.1 | ND | No |
| 11 | 76/M | C | 84 | 93 | 93 | 92+ | 93 | 65 | 71+/0 | 20 | 5 | No | No |
| 12 | 80/M | C | 198 | 99 | 97 | 0 | 0 | 3 | 1/75+ | 2 | 5.5 | ND | No |
| 13 | 83/F | A | 170 | 99 | 97 | 49+ | 51 | 0 | 71+/0 | 60+ | 9.8 | ND | No |
| 14 | 42/F | B | 141 | 97 | 94 | 65+ | 45 | 15 | 83+/0 | 34 | 1.4 | No | No |
| 15 | 85/F | A | 98 | 97 | 93 | 40+ | 46 | ND | 47+/0 | ND | 5.9 | ND | No |
| 16 | 76/F | A | 194 | 90 | 87 | 74+ | 51 | 4 | 93+/++/0 | 87++ | 5.9 | Yes | No |
| 17 | 65/M | C | 38 | 99 | 95 | 69+ | 69 | 2 | 0/80+/++ | 4 | 12.8 | No | CLB |
| 18 | 74/F | C | 510 | 93 | 94 | 74 | 50 | 20 | 20+/0 | 55+ | 7 | ND | No |
| 19 | 73/M | A | 29 | 80 | 83 | 80+ | 67 | 0 | 0/60+ | 53 | 6 | Yes | CLB |
| 20 | 86/F | A | 18 | 97 | 88 | 91+ | 91 | 20 | 59+/0 | 68+ | 4 | Yes | No |
| Patient No. . | Age/ Sex . | Stage* . | WBC . | CD5 . | CD19 . | CD22 . | CD23 . | FMC7 . | κ/λ . | CD79b . | β2M . | +12 . | Previous Treatment . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 72/M | A | 180 | 99 | 90 | 93+ | 50 | 2 | 0/93++ | 84++ | 6.4 | Yes | CLB |
| 2 | 61/M | A | 68 | 95 | 84 | 77+ | 85 | 4 | 79+/0 | 27dim | 2 | ND | No |
| 3 | 67/F | C | 163 | 68 | 90 | 15 dim | 87 | 0 | 0/88 | 19 | ND | No | No |
| 4 | 77/F | A | 107 | 85 | 59 | 38+ | 43 | 14 | 17/0 | ND | 2 | ND | No |
| 5 | 63/F | A | 87 | 97 | 90 | 84+/++ | 64 | 5 | 63/0 | ND | ND | ND | No |
| 6 | 69/F | A | 19 | 94 | 69 | 74 | 25 | 6 | 45+/0 | 53+ | ND | No | No |
| 7 | 47/M | B | 425 | 96 | 95 | 70+ | 95 | 7 | 0/93+/++ | ND | 5.4 | ND | 2-CDA |
| 8 | 70/M | A | 31 | 91 | 87 | 88+ | 78 | 14 | 86+/0 | ND | 6.2 | No | CLB/PDN; FLU |
| 9 | 47/M | B | 18 | 97 | 92 | 54+ | 90 | 16 | 54+/0 | ND | 2.5 | ND | CLB; FLU |
| 10 | 84/F | A | 154 | 96 | 93 | 93+ | 41 | 0 | 91+/0 | 90+ | 4.1 | ND | No |
| 11 | 76/M | C | 84 | 93 | 93 | 92+ | 93 | 65 | 71+/0 | 20 | 5 | No | No |
| 12 | 80/M | C | 198 | 99 | 97 | 0 | 0 | 3 | 1/75+ | 2 | 5.5 | ND | No |
| 13 | 83/F | A | 170 | 99 | 97 | 49+ | 51 | 0 | 71+/0 | 60+ | 9.8 | ND | No |
| 14 | 42/F | B | 141 | 97 | 94 | 65+ | 45 | 15 | 83+/0 | 34 | 1.4 | No | No |
| 15 | 85/F | A | 98 | 97 | 93 | 40+ | 46 | ND | 47+/0 | ND | 5.9 | ND | No |
| 16 | 76/F | A | 194 | 90 | 87 | 74+ | 51 | 4 | 93+/++/0 | 87++ | 5.9 | Yes | No |
| 17 | 65/M | C | 38 | 99 | 95 | 69+ | 69 | 2 | 0/80+/++ | 4 | 12.8 | No | CLB |
| 18 | 74/F | C | 510 | 93 | 94 | 74 | 50 | 20 | 20+/0 | 55+ | 7 | ND | No |
| 19 | 73/M | A | 29 | 80 | 83 | 80+ | 67 | 0 | 0/60+ | 53 | 6 | Yes | CLB |
| 20 | 86/F | A | 18 | 97 | 88 | 91+ | 91 | 20 | 59+/0 | 68+ | 4 | Yes | No |
Immunophenotype is expressed in percentage of positive cells: +, less intense than normal; ++, normal intensity.
Abbreviations: WBC, white blood cell count (109/L); β2M, β2microglobulin (mg/L); +12, trisomy 12; CLB, chlorambucil; PDN, prednisone; 2-CDA, 2-chlorodesoxiadenosine; FLU, fludarabine; ND, not determined.
According to Binet’s classification.